Sanofi’s Amlitelimab Study Termination: Implications for Investors

Sanofi (SNYNF) announced an update on their ongoing clinical study.

Sanofi’s recent clinical study, officially titled ‘A Phase 2, Randomized, Double-blind, Placebo-controlled, Parallel Group, Proof-of-concept Study Assessing the Efficacy and Safety of Amlitelimab in Adult Participants With Moderate to Severe Hidradenitis Suppurativa,’ aimed to evaluate the efficacy and safety of amlitelimab. This study focused on participants with moderate to severe hidradenitis suppurativa, a chronic skin condition, to measure both clinician and participant-reported outcomes.

The intervention being tested was a subcutaneous injection of amlitelimab, an experimental drug, compared to a placebo. Amlitelimab is intended to treat moderate to severe hidradenitis suppurativa by potentially reducing inflammation and symptoms associated with the condition.

The study was designed as an interventional, randomized, parallel-group trial with a quadruple masking approach, meaning that participants, care providers, investigators, and outcomes assessors were all blinded to the treatment allocation. The primary purpose was treatment-focused, aiming to assess the drug’s impact on the condition.

The study began on October 31, 2023, but was terminated before reaching primary completion. The last update was submitted on November 4, 2025. These dates are crucial as they mark the study’s initiation and its most recent status update, indicating its current standing in the clinical trial process.

The termination of this study could impact Sanofi’s stock performance and investor sentiment, as it may signal challenges in developing amlitelimab for hidradenitis suppurativa. Investors might compare this with competitors’ progress in similar therapeutic areas to gauge market positioning.

The study has been terminated, and further details are available on the ClinicalTrials portal.

To learn more about SNYNF’s potential, visit the Sanofi drug pipeline page.